Uncommon Immune-Mediated Disease 2) Pure Red Cell Aplasia

1. Etiology

  • ==Erythroid precursors์ด ์•„์˜ˆ ์—†๊ฑฐ๋‚˜, ๋‘๋“œ๋Ÿฌ์ง€๊ฒŒ ๊ฐ์†Œํ•˜์—ฌ ๋‚˜ํƒ€๋‚˜๋Š” ์‹ฌ๊ฐํ•œ nongernerative anemia==
  • Spherocytes๊ฐ€ ๋ณด์ด๊ฑฐ๋‚˜, Coombs test ์–‘์„ฑ์ผ ์ˆ˜๋„ ์žˆ๋‹ค. (๋Œ€๋ถ€๋ถ„์˜ Coombs test๋Š” ์Œ์„ฑ)
  • IMHA์˜ ํฐ ๋ฒ”์ฃผ ์•ˆ์— PRCA๊ฐ€ ์žˆ๋‹ค๊ณ  ์—ฌ๊ฒจ์ง€๊ณ  ์žˆ๋‹ค.

์ผ๋ฐ˜์ ์ธ IMHA์™€ ๊ตฌ๋ถ„๋˜๋Š” ์ 

  • ๋น„์žฌ์ƒ์„ฑ IMHA : maturation arrest๊ฐ€ ๋‚˜ํƒ€๋‚จ - rubricyte๋‚˜ metarubricyte level์—์„œ ๋ฉˆ์ถฐ ์žˆ์Œ.
  • PRCA : ์–ด๋А ๋‹จ๊ณ„์—์„œ๋ถ€ํ„ด๊ฐ€ ์ „๋ถ€ ์—†์Œ. Erythroid precursor๊ฐ€ ๊ฑฐ์˜ ์•„์˜ˆ ์—†์–ด์ง€๋Š” ๊ฒƒ์ด ํŠน์ง•!

Fig. IMHA์˜ ๋ฒ”์ฃผ์— ๋Œ€ํ•œ ๊ฒฝํ–ฅ์„ฑ

  • Classical IMHA : ์žฌ์ƒ์„ฑ, spherocytes, Coombs ์–‘์„ฑ, ํ™ฉ๋‹ฌ ๋“ฑ
  • NRIMA/PIMA (๋น„์žฌ์ƒ์„ฑ IMHA/precursor ์ƒํƒœ์—์„œ IMHA) : ๋น„์žฌ์ƒ์„ฑ, maturation arrest, myelofibrosis๊ฐ€ ์กฐ๊ธˆ ๋” ํ”ํ•จ, ๋‹ค๋ฅธ ์„ธํฌ์— ์˜ํ–ฅ ์กด์žฌ
  • PRCA : ๋น„์žฌ์ƒ์„ฑ, myelofibrosis ๋œ ํ”ํ•จ, Erythroid precursor๊ฐ€ ๊ฑฐ์˜ ์—†์Œ, ๋‹ค๋ฅธ ์„ธํฌ์— ์˜ํ–ฅ ๊ฑฐ์˜ ์—†์Œ
  • Erythroid precursor์— ๋Œ€ํ•œ ํ•ญ์ฒด์˜ ์นœํ™”๋ ฅ(affinity)๊ฐ€ ๋ณ‘์˜ ์‹ฌ๊ฐ๋„๋ฅผ ๊ฒฐ์ •ํ•œ๋‹ค.
  • Secondary causes
    • Dogs
      (1) ์‹ ์žฅ ๊ธฐ๋Šฅ์ด ๋–จ์–ด์ ธ Epo ํ™œ์„ฑ ๊ฐ์†Œ โ†’ ์žฌ์กฐํ•ฉ human EPO๋ฅผ ๋ฐ˜๋ณต ์ฃผ์‚ฌํ•˜๋‹ค๊ฐ€ ๋ฉด์—ญ ๋ฐ˜์‘์ด ๋ฐœ์ƒ
      (2) Parvovirus infection โ†’ ๊ฐœ์˜ ์ ํ˜ˆ๊ตฌ์— ์˜ํ–ฅ์„ ๋ฏธ์นจ
    • Cats : Feline leukemia virus subtype C (๊ณ ์–‘์ด์—์„œ๋„ ์†๋ฐœ์„ฑ์œผ๋กœ ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ์Œ)
  • Dogs with PRCA : IMHA์™€ ๋น„์Šทํ•œ ์ฆ์ƒ
  • Cats with primary PRCA: ๊ฐœ๋ณด๋‹ค ๋” ์–ด๋ฆฐ ๋‚˜์ด์—์„œ ๋‚˜ํƒ€๋‚œ๋‹ค. (8๊ฐœ์›”~3๋…„๋ น)
  • ์‹ฌ๊ฐํ•˜๊ณ  ๋น„์žฌ์ƒ์„ฑ์ธ ๋นˆํ˜ˆ์„ ๋‚˜ํƒ€๋‚ด๋‚˜, ๋‹ค๋ฅธ ๊ฒ€์‚ฌ ์ˆ˜์น˜์—์„œ ๊ฑฐ์˜ ์ด์ƒ์„ ๋‚˜ํƒ€๋‚ด์ง€ ์•Š๋Š”๋‹ค. (platelet count, leukogram, biochemical panel, urinalysis ๋“ฑ / ๋ง์ดˆ ์šฉํ˜ˆ์ด๋‚˜ ์—ผ์ฆ ์†Œ๊ฒฌ๋„ ์—†์Œ)
  • ์ข…์ข… ์ ์€ ์ˆ˜์˜ spherocytes๋„ ๋‚˜ํƒ€๋‚œ๋‹ค.
  • Coombs tests๋Š” ๋Œ€๋ถ€๋ถ„ ์Œ์„ฑ์ด๋‚˜, ์–‘์„ฑ์ผ ์ˆ˜๋„ ์žˆ๋‹ค.
  • Diagnosis : bone marrow aspirate & core biopsy
    • Erythroid precursor ์—†๊ฑฐ๋‚˜ rare
    • M:E ratio๊ฐ€ ๋†’์Œ (>99:1)
    • ์‹ฌํ•œ myelofibrosis๋Š” ๋“œ๋ฌผ๋‹ค.

2. Treatment

  • IMHA์™€ ์œ ์‚ฌํ•˜๋‚˜, PDS + ๋ณด์กฐ ๋ฉด์—ญ์–ต์ œ์ œ๋ฅผ ์‚ฌ์šฉํ–ˆ๋˜ IMHA์™€ ๋‹ฌ๋ฆฌ PRCA์—์„œ๋Š” PDS ๋‹จ๋… ์น˜๋ฃŒ์— ๋Œ€ํ•œ ๋ฐ˜์‘์ด ์ข‹์€ ํŽธ.
  • ๋ณดํ†ต PDS ๋‹จ๋… ์น˜๋ฃŒ โ†’ ์ข…์ข… ๋ฐ˜์‘ ์•ˆ ์ข‹์„ ๋•Œ ๋ณ‘์šฉ ์•ฝ๋ฌผ ์ด์šฉ.
  • Adjunctive immunosuppressive : azathioprine, cyclophosphamide, cyclosporine, mycophenolate ๋ฅผ ์‚ฌ์šฉํ•  ๋•Œ๋„ ์žˆ์Œ.
  • ์น˜๋ฃŒ๋Š” 2-6๊ฐœ์›” ์†Œ์š”๋˜๊ณ , ์ฆ์ƒ ์ง„ํ–‰์ด ๋А๋ฆฌ๋“ฏ ๊ฐœ์„  ๋ฐ˜์‘๋„ ๋А๋ฆฌ๋‹ค.
    • ์•ฝ๋ฌผ์ด ๋“ฃ์ง€ ์•Š๋Š” ๊ฑด์ง€, ๊ณจ์ˆ˜๊ฐ€ ์น˜๋ฃŒ์— ๋ฐ˜์‘ํ•˜๊ธฐ๊นŒ์ง€ ์‹œ๊ฐ„์ด ๋” ํ•„์š”ํ•œ์ง€ ํŒ๋‹จ์„ ์š”๊ตฌํ•จ.
  • ==๊ณจ์ˆ˜ ๊ฒ€์‚ฌ==๊ฐ€ ํ•„์š”ํ•˜์ง€๋งŒ, ํ˜„์‹ค์ ์œผ๋กœ ์‰ฝ๊ฒŒ ํ•˜์ง€๋Š” ๋ชปํ•จ : ์›์น™์ ์œผ๋กœ ์•ฝ๋ฌผ ๋ณ€๊ฒฝํ•˜๋ ค๊ณ  ํ•  ๋•Œ ๊ณจ์ˆ˜ ๊ฒ€์‚ฌ๋ฅผ ์‹œํ–‰ํ•ด์•ผ ํ•œ๋‹ค. 2๊ฐœ์›” ์ด์ƒ ๊ฐœ์„ ์ด ์—†์œผ๋ฉด ๊ณจ์ˆ˜ ๊ฒ€์‚ฌ๊ฐ€ ๊ถŒ์žฅ๋œ๋‹ค.
  • ํ•ญ์‘๊ณ ์ œ(anticoagulant)๋Š” ์ง€์‹œ๋˜์ง€ ์•Š์Œ : PRCA์—์„œ๋Š” IMHA์—์„œ์™€ ๋‹ฌ๋ฆฌ TE(ํ˜ˆ์ „์ƒ‰์ „์ฆ) ์œ„ํ—˜ ์ฆ๊ฐ€๋‚˜ systemic inflammation์€ ๋‚˜ํƒ€๋‚˜์ง€ ์•Š๋Š”๋‹ค.
  • ์˜ˆํ›„
    • Dogs : mortality <20%, IMHA๋ณด๋‹ค๋Š” ์˜ˆํ›„๊ฐ€ ์ข‹๋‹ค. ์น˜๋ฃŒ ๋น„์šฉ์ด ๋†’์•„ ์•ˆ๋ฝ์‚ฌ๋˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ๋‹ค ๐Ÿ˜ฟ
    • Cats : ๊ฐœ๋ž‘ ๋น„์Šทํ•˜์ง€๋งŒ, ์กฐ๊ธˆ ๋” ๋ฐ˜์‘์ด ๋น ๋ฅด๊ณ (1.5~5์ฃผ), ์žฌ๋ฐœ ๊ฐ€๋Šฅ์„ฑ๋„ ์ข€ ๋” ๋†’๋‹ค.
      • Azathioprine ๊ณ ์–‘์ด์—์„œ ๊ธˆ์ง€ โ†’ ๋ณด์กฐ ๋ฉด์—ญ์–ต์ œ์ œ๋กœ cyclophosphamide์™€ cyclosporine ์‚ฌ์šฉํ•œ๋‹ค!